51results about How to "Improve dissolution behavior" patented technology

The invention provides compositions containing polypeptides, including therapeutic polypeptides such as interleukin-11, that are suitable for oral administration.

A scaffold of the granular anticancer medicine for treating the benign or malignant stenosis of esophagus and digestive tract is disclosed, which has 4 structures consisting of scaffold, granular anticancer medicine, selective coated film on the surface of scaffold, and selective external protective layer.

A method for electrochemically etching a metal layer through an etch-resist layer pattern using a non-active electrolyte solution is described. The method is particularly useful in fabrication of advanced fuel delivery systems for land-based power generation turbines and aerospace turbine engines; of components for advanced thermal management in aerospace electronic devices and in cooling channels; of stents used in medicine; and of microchannels for sensors, chemical reactors, and dialysis and the like. In one embodiment of the invention the metal layer is copper and the non-active electrolyte solution is a mixture of sodium nitrate and sodium chloride and a pulse electric current is employed to accomplish the electrochemical etching.

The invention discloses a phosphate tetrahydroberberine drug eutectic and a preparation method thereof. The tetrahydroberberine and phosphate are added and mixed in isopropanol water solution, ethanol water solution or methanol water solution according to the molar ratio; the acquired mixed solution is volatilized under the room temperature. The prepared tetrahydroberberine drug eutectic is a triclinic system, and the space group is P-1, and its axial length (i) is FORMULA; the axial angle is FORMULA. The tetrahydroberberine drug eutectic prepared by the invention inherits the pharmacological activity of tetrahydroberberine, its solubleness, dissolution rate, antibiosis bacillus coli and staphylococcus aureus activities are significantly improved in relative to the tetrahydroberberine, thereby saving drug dosage; the method is good for developing to be drug preparation, and the tetrahydroberberine can be widely applied to the medicine field.

The invention discloses levofloxacin hydrochloride tablets which comprise an active ingredient levofloxacin hydrochloride and medicinal auxiliary materials, wherein the medicinal auxiliary materials comprise a filling agent, a disintegrating agent and a lubricating agent. In the large-scale production of tablets, magnesium stearate generally serves as the lubricating agent, however, because magnesium ion is extremely easily subjected to complexation with levofloxacin or salts thereof, the activity of the medicine is reduced, absorption of gastrointestinal tract on the medicine is interfered, and levofloxacin hydrochloride is unsuitable to be compatible with magnesium stearate. According to the research, when other conventional lubricating agents are used for large-scale preparation in the conventional technology, tests show that the conditions such as severe sticking, bonding, bouncing and low core friability occur in the process of tabletting levofloxacin hydrochloride exist. According to the research in the invention, the lubricating agent adopts talc powder and stearic acid which are added according to a specific compatibility ratio, the lubricating agent has excellent quality controllability in the large-scale production process of the levofloxacin hydrochloride tablets through tests, and the prepared levofloxacin hydrochloride tablets have high safety and effectiveness.

The invention provides a medicinal composition containing lenvatinib. The medicinal composition comprises, by weight, 1-20% of lenvatinib mesylate, 20-60% of anhydrous calcium hydrogen phosphate, 10-55% of a filler, 5-35% of a disintegrating agent, 0-10% of an adhesive and 0.5-5% of a lubricant. Preferably, the particle size of the anhydrous calcium hydrogen phosphate is 200-600 meshes, or the D90 is about 20-75 [mu]m. The medicinal composition has good stability, has a dissolubility reaching 90% or above in 15 min, has effectively improved bioavailability, is easy to prepare, and is suitable for industrial production.

The invention relates to the field of medicinal preparations and particularly relates to a montelukast sodium chewable tablet, apreparation method and a determination method of a dissolution rate. Raw materials of the montelukast sodium chewable tablet comprise montelukast sodium, mannitol, microcrystalline cellulose, hydroxy propyl cellulose, crosslinking sodium carboxymethylcellulose, aspartame, ferric oxide, magnesium stearate and cherry essence. The hydroxy propyl cellulose is prepared into a solution with a mass percentage content being 6-8% through water being a solvent and a disintegrating agent is prepared through a wet process of an internal addition method. The montelukast sodium chewable tablet is significantly increased in disintegrating speed and in-vitro dissolution rate. By means of a dissolution curve detection method, quality differences among products in each batch can be effectively distinguished. Differences between products in each batch can be reduced better and a quality risk of the products can be controlled in a controllable range.

The invention relates to a solid preparation of ticagrelor or its pharmaceutically acceptable salt. Ticagrelor or its pharmaceutically acceptable salt is used as a main drug, lactose, partly pregelatinized starch, hydroxypropyl methyl cellulose, silica and talcum powder are used as auxiliary materials, and powder of the above materials are directly pressed to form a tablet.

The invention discloses a method for preparing telmisartan and amlodipine double-layer tablets. The double-layer tablets comprise a telmisartan layer and an amlodipine besylate layer, wherein the telmisartan exists in a solid dispersion form. According to the method for preparing telmisartan and amlodipine double-layer tablets provided by the invention, good dissolution behaviors of the telmisartan and amlodipine besylate are guaranteed, and high stability of the amlodipine besylate is also guaranteed, so that the quality and curative effects of the telmisartan and amlodipine double-layer tablets are ensured. The preparation method is simple and feasible and is suitable for industrial production.

The invention discloses a toluenesulfonic acid edoxaban tablet and a preparation method thereof. Raw materials of the toluenesulfonic acid edoxaban tablet include the following substances by mass: 20.2 parts of toluenesulfonic acid edoxaban, 10.1-101 parts of polymeric carrier, 2.02-10.1 parts of surfactant, 30-45 parts of filler and 0.4-0.8 part of lubricant. The polymeric carrier is preferably amixture of PVP K-30 and HPMCAS with the mass ratio of (2-4):1. The preparation method includes dissolving the toluenesulfonic acid edoxaban, the polymeric carrier and the surfactant in a solvent; spraying and drying to obtain a solid dispersion of the toluenesulfonic acid edoxaban; 2) mixing the solid dispersion of the toluenesulfonic acid edoxaban with other accessories and conducting tabletting. The tablet can significantly improve the dissolution rate and the solubility of a drug, increase the drug absorption and improve the bioavailability. In particular, the tablet significantly improvesthe dissolution behavior in a buffer solution of neutral pH 6.8 compared with the existing preparations.

The invention relates to a solid preparation of clopidogrel or a pharmaceutically acceptable salt thereof, and the adopted technical scheme is as follows: taking the clopidogrel or the pharmaceutically acceptable salt as a principal agent, taking lactose, partially pregelatinized starch, hydroxypropyl methyl cellulose, silicon dioxide and talcum powder as excipients, and directly pressing powder into tablets.

Disclosed is a pharmaceutical preparation having 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazine-1-yl-pyridine-2-yl amino group)-8H-pyrido[2,3-d]pyrimidine-7-one or salt thereof as an active ingredient, the salt comprising hydrochloride or isethionate, and the dosage form thereof comprising tablets and capsules both having good stability and excellent dissolution performance.

The invention provides a repaglinide and metformin hydrochloride tablet pharmaceutical composition; in a prescription, the amount of a disintegrating agent is greatly reduced compared with the prior art; in a process, microcrystalline cellulose particles are prepared in advance, repaglinide is made into a solution, repaglinide particles are prepared on the microcrystalline cellulose particles through fluidized bed atomizing, and the repaglinide particles are mixed and tabletted with metformin hydrochloride particles. The prepared repaglinide and metformin hydrochloride tablet product is stable, the insoluble drug repaglinide and the water-soluble drug metformin hydrochloride are both released synchronously according to requirements, and the bioavailability is better compared with that of the prior art; and at the same time, the problem of uneven mixing of the low-dosage drug repaglinide is solved, and the drug efficacy playing is greatly promoted.

Belonging to the field of pharmaceutical preparations, the invention provides a preparation method for a drug A (formula 1) powder and its application in oral solid preparations. The method includes: dispersing the crude drugs of drug A in a hydrophilic suspending aid solution, employing wet grinding to reduce the particle size to less than 5 micrometers, adding a spray-drying support agent, and combining spray drying, thus obtaining the drug A powder with an average particle size of less than 20 micrometers. The drug A powder prepared by the invention has high surface hydrophilicity, small particle size and good redispersibility in water. Compared with the crude drugs, the oral solid preparations prepared from the drug A powder and suitable auxiliary materials can significantly improve the dissolution rate. The preparation method for the drug A powder provided by the invention is suitable for industrial production and has high application value. (formula I).

The present invention relates to the field of medicines, particularly to a folic acid solid dispersion body and a preparation method thereof, wherein the solid dispersion body comprises a hydrophilic carrier and folic acid, a weight ratio of the folic acid to the hydrophilic carrier is 1:5-1:50, and the hydrophilic carrier is one or a composition comprising one or a plurality of materials selected from poloxamer, polyethylene glycol, povidone and mannitol. According to the present invention, the particle size distribution of the folic acid solid dispersion body is 80-150 mesh; the preparation method is a melting method or a grinding method; the clinical preparation form of the solid dispersion body is an oral solid preparation, and the 30 min dissolution of the oral solid preparation is not less than 90%; and the folic acid solid dispersion body of the present invention has comprehensive advantages of uniform content, good dissolution, high bioavailability and good stability, and the characteristics of environmental protection and easy industrialization achieving are provided.